Medico Remedies logo

Medico Remedies financials and balance sheet

NSE: MEDICOBSE: 540937Pharmaceuticals & BiotechnologySmall Cap

Last close ₹19.90down ₹0.60 (2.93%)BSE ₹20.17

Share price at the NSE close on 23 Oct 2026. Previous close ₹20.50.

52-week range of traded prices to 23 Oct 2026
₹19.11Low, 23 Oct 2026₹56.88High, 24 Dec 2025
Market cap
₹165 Cr2,034th largest listed
P/E
12.0
P/B
2.2
Dividend yield
Nonein the last 12 months
ROE
20.1%
ROCE
15.3%
Debt to equity
0.25
Volume, NSE
1,57,78351.0% delivered

9 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Medico Remedies annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹206 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 4.8% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue206
  2. Materials and goods−151
  3. Employee costs−7.4
  4. Other expenses−31
  5. Operating profit17
  6. Depreciation−3.1
  7. Other income+5.9
  8. One-off items0.0
  9. Finance costs−1.8
  10. Profit before tax18
  11. Tax−4.9
  12. Net profit13

What the company owns

  • Receivables₹82 Cr
  • Plant, investments and other assets₹38 Cr
  • Inventory₹30 Cr
  • Cash and bank₹2 Cr
  • Current investments₹2 Cr

What pays for it: net worth and liabilities

  • Net worth₹75 Cr
  • Owed to suppliers₹49 Cr
  • Borrowings₹19 Cr
  • Other liabilities₹10 Cr

Profit and loss

Standalone, ₹ crore, years to March.Medico Remedies quarterly results

₹ croreMar 2018Mar 2019Filed 29 MayMar 2020Filed 29 JunMar 2021Filed 28 MayMar 2022Filed 24 MayMar 2023Filed 17 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 21 May
Revenue from operations619889122121140145151206
58–––114131132136189
Materials and goods bought4380679287105110108151
Employee costs4–––56667
Other expenses10–––2120162131
Operating profit before depreciation3–––710131517
Operating margin5.7%–––6.0%6.9%8.9%9.9%8.3%
Materials, % of revenue71.3%–––72.1%74.7%75.8%71.8%73.3%
Employee costs, % of revenue6.4%–––4.5%4.0%4.1%4.2%3.6%
Other expenses, % of revenue16.6%–––17.4%14.4%11.2%14.1%14.8%
Depreciation and amortisation1–––23333
Operating profit after depreciation2–––57101214
Other income122124236
Finance costs211111112
One-off items–––––0000
Profit before tax2224710111418
111123335
Net profit12235781013
Other comprehensive income–––––0000
Total comprehensive income–––––791013
Net margin2.0%1.6%1.8%2.1%4.0%5.2%5.7%6.7%6.4%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Filed 29 MayMar 2020Filed 29 JunMar 2021Filed 28 MayMar 2022Filed 24 MayMar 2023Filed 17 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 21 May
2830323744526275
Share capital4441717171717
Reserves2426282127364659
131213111081519
4540383842435778
35512100
Total assets767576768796120153
1719171823222324
59575959657497129
Net debt121098871215
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 28 MayMar 2022Filed 24 MayMar 2023Filed 17 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 21 May
2.66.08.22.44.95.9
3.87.910.75.78.810.9
−1.7−1.0−2.9−9.3−7.2−10.3
Receivables−3.5−3.9−5.7−13.6−7.0−25.1
Inventories3.7−3.6−1.63.4−10.4−3.3
Payables−1.11.73.90.53.214.6
Other working capital−0.94.70.50.56.93.5
Tax paid−1.2−1.8−2.5−3.2−3.8−5.1
Capital spending2.15.90.00.00.00.0
Free cash flow0.50.18.22.44.95.9
−0.1−2.1−6.6−2.7−3.5−4.5
−0.4−5.6−1.8−0.5−0.5−0.6
Dividends paid0.00.00.00.00.00.0
Shares bought back––0.00.00.00.0
Shares issued0.00.00.00.00.00.0
Net change in cash2.2−1.7−0.3−0.70.90.8
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2018Mar 2019Filed 29 MayMar 2020Filed 29 JunMar 2021Filed 28 MayMar 2022Filed 24 MayMar 2023Filed 17 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 21 May
––––₹0.59₹0.87₹1.00₹1.22₹1.58
As stated that year₹3.65₹3.78₹3.93₹6.25₹2.95₹0.87₹1.00₹1.22₹1.58
––––₹0.59₹0.87₹1.00₹1.22₹1.58
––––₹4.50₹5.28₹6.31₹7.51₹9.10
Shareholder yield–––0.0%0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)40353041139623399428272
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.Medico Remedies PE ratio and valuation

RatioMar 2018Mar 2019Filed 29 MayMar 2020Filed 29 JunMar 2021Filed 28 MayMar 2022Filed 24 MayMar 2023Filed 17 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 21 May
Revenue growth–60.1%−9.3%38.1%−1.1%16.0%3.2%4.2%36.7%
Operating profit growth–––––33.5%34.2%16.2%13.5%
Net profit growth–28.7%3.8%59.0%88.6%48.1%14.5%21.7%29.9%
Earnings per share growth–––––47.5%14.9%22.0%29.5%
–5.6%5.6%8.3%14.0%17.8%17.2%17.6%19.0%
––0.1 pts2.7 pts5.7 pts3.8 pts−0.6 pts0.4 pts1.4 pts
From the net margin––0.8 pts0.8 pts7.5 pts3.9 pts2.0 pts2.9 pts−0.9 pts
From asset turnover––−0.6 pts2.5 pts−0.3 pts1.4 pts−1.6 pts−2.3 pts1.4 pts
From borrowing––−0.2 pts−0.6 pts−1.6 pts−1.4 pts−1.0 pts−0.2 pts1.0 pts
Return on capital employed––––10.7%12.9%16.6%15.6%14.8%
Cash conversion–––100.6%123.4%112.8%29.4%48.5%44.8%
Interest cover1.6–––8.49.212.210.37.7
Debt to equity–0.450.400.400.280.220.150.240.25
Receivable days–10998829494125138145
Inventory days–7499587669549072
Payable days–––––108105117119
Cash conversion cycle, days–––––557511198
Working capital days–879074857692125117
Asset turnover–1.281.171.621.591.721.581.401.51
Assets per rupee of net worth–2.702.612.422.182.021.911.881.98
Sales per rupee of plant–7.425.987.997.526.927.157.3510.27
Capital spending to depreciation––––2.840.000.000.000.00
Plant being built, % of plant in use–––––7.5%5.5%5.1%12.8%
No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
9.6%
Cash from operations against operating profit
34.5%
Measure10 years5 years3 years
Revenue growth, yearly rate–11.0%13.7%
Profit growth, yearly rate–38.3%21.9%
Return on equity, average–17.1%18.0%
Return on capital employed, average–14.1%15.6%
Operating margin, average–8.0%9.0%
Net margin, average3.9%5.6%6.3%
Asset turnover, average–1.561.50
Cash conversion cycle, days, average–8595
Interest cover, average–9.610.1
Debt to equity, average–0.230.21

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations27.413.25.9
Cash from investing−19.4−10.6−4.5
Cash from financing−9.0−1.6−0.6
Capital spending5.90.00.0
Dividends paid0.00.00.0
Shares bought back–0.00.0
Shares issued for cash0.00.00.0
Borrowings raised0.00.00.0
Borrowings repaid6.70.00.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––––566
Altman Z-scorePublished threshold 1.81–––––11.348.307.084.80
Beneish M-scorePublished threshold −1.78––––––−1.91−2.34−1.66
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––––6.949.298.038.61
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––0.600.42
Receivables growth less revenue growthOur threshold 0 percentage points––−8.55−23.2915.27−0.7534.3111.056.66
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––29.13−57.5229.75−11.35−21.8765.03−27.38
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––−0.39−0.33−4.86−0.27−0.252.641.38
Assets under construction, years of additionsOur threshold 2 years of additions––––––0.390.320.97
Effective tax ratePublished threshold 17.16 per cent34.8627.8126.4029.6825.3528.2926.8525.2627.38
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––−2.513.59−1.08−2.90−0.62
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
4 Jun 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil A3Review, Re-affirm5
4 Jun 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil BBB-Review, Re-affirmStable19
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.